Target of Rapamycin and developmental mTORopathies

The Bordey Lab has been focused on the mammalian Target of Rapamycin, mTOR. mTOR is a converging point in cell signaling, or in other terms an intracellular hub, that receives signals from diverse intracellular routes and extracellular ligands. Importantly, mTOR is dysregulated in many neurological disorders. These disorders referred to as mTORopathies include (but are not limited to) Tuberous Sclerosis Complex (TSC), autism, Alzheimer’s disease, and Schizophrenia. We have focused on TSC. Dr. Angélique Bordey holds the rank of Professor of Neuroscience at the Yale School of Medicine.

Image courtesy of interviewee

Leave a Reply

Your email address will not be published.

×
Guest visitors to the Faculti website can view any insight monthly. You have insight(s) remaining for this month

Register for free as an individual and view thousands of insights in our archive today or subscribe for subject access.

You may already have institutional access to Faculti. Please access Faculti using your institution credentials.

Copyright © Faculti Media Limited 2022. All rights reserved.
Recommend Faculti to your librarian

error:

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×